

CHEST® Curriculum Pathway for Asthma

Publication date: July 21, 2025 Product expiration date: July 20, 2028 Title: CHEST Curriculum Pathway for Asthma

Chair: Malvika Kaul, MD

Course Description

Start learning with the CHEST Curriculum Pathway for Asthma. Follow the nine paths from start to finish for a comprehensive overview of asthma diagnosis and management. Or, select the individual paths that best fit your daily work and clinical interests. Choose from topics like pathophysiology, exacerbations, and phenotypes.

The pathway offers a variety of bite-sized educational resources you can review in 20 minutes or less. Explore case-based CHEST SEEK® questions, podcasts and videos from asthma experts, and research from the journal CHEST®.

Course Objectives

This curriculum is comprised of 8 "Paths," each intentionally developed by CHEST's Asthma Pathway Work Group to address the needs of clinicians in all phases of their careers. All activities are open to all clinicians who wish to enhance their practice by learning more about asthma. Progressing through the curriculum will be a different experience for each learner. For example, some learners may start at Path 1 and finish at Path 3, as those are the only topics relevant to their current practice. While other learners may simply need a "refresher" on Mimickers and Comorbidities, for example, in which case they would take Paths 4 and 5. The complete list of Paths is below:

Like a standard CME activity, the CHEST team has identified important learning objectives for each Path. For example:

Path 1, Pathophysiology:

- 1) Recognize the various asthma phenotypes.
- 2) Recognize the biomarkers used to identify the Th2 phenotype.
- 3) Review understanding of asthma pathobiology.

Path 2, Diagnosis & Classification:

- 1) Identify key symptoms and diagnostic criteria for asthma.
- 2) Compare and contrast uncontrolled asthma and severe asthma.
- 3) Recognize asthma mimics.
- 4) Differentiate between the proper inhaler technique for the aerosol devices, dry powder inhalers, and nebulizers.

Path 3, Management:

- 1) Recognize the optimal step-wise therapy for patients with persistent asthma.
- 2) Select the most appropriate advanced therapies for severe asthma with Th2 high phenotype.
- 3) Identify options for advanced therapies for patients with severe asthma with Th2 low phenotype.
- 4) Recognize complications associated with chronic oral corticosteroids use and outline a practical approach to management of oral corticosteroids-dependent asthma.

Path 4, Mimickers:

- 1) Recognize mimickers of asthma.
- 2) Differentiate asthma mimickers from true asthma.

Path 5, Comorbidities:

- 1) Recognize comorbidities associated with asthma.
- 2) Identify the best ways to assess, diagnose, and manage common comorbidities associated with asthma.

Path 6, Phenotypes of Asthma:

- 1) Differentiate between phenotypes and endotypes of asthma and how to apply this knowledge directly to the clinical arena.
- 2) Recognize the various asthma phenotypes.
- 3) Differentiate phenotypes of asthma based on information from clinical scenarios.

Path 7, Exacerbations:

- 1) Discuss how to triage patients with asthma exacerbations to determine severity.
- 2) Identify appropriate treatment for asthma exacerbations.
- 3) Apply advanced interventions, including mechanical ventilation and extracorporeal life support, in cases of severe or near-fatal asthma.

Path 8, Other (Special Situations):

- 1) Outline a pragmatic framework for the evaluation and management of pediatric patients with severe asthma.
- 2) Review choices for advanced therapy options for pediatric patients with severe asthma.
- 3) Recognize possible complications from chronic therapies, such as systemic corticosteroids, prescribed in patients with asthma.
- 4) Identify potential complications of asthma care.

Path 9, Optional Learning Path:

- 1) Define asthma, its epidemiology, and risk factors.
- 2) Demonstrate proper use of inhalers and nebulizers.
- 3) Diagnose to treat cases of severe asthma.

Participation Feedback

The participation threshold or passing standard for this course includes learner completion of the final self-assessment and learner completion of the CME credit evaluation, including the identification of what changes the learner expects to make in practice due to participation in this course.

Maintenance of Licensure

Maintenance of Credit (MOC) offered in Pulmonary Medicine Education.

FACULTY

Chair/Planner

Malvika Kaul, MD

Assistant Professor of Clinical Medicine
Division of Pulmonary, Critical Care, Sleep and Allergy
Department of Medicine
University of Illinois at Chicago
Chicago, IL

Faculty/Planners

Javier Torres Berríos, MD

Pulmonary and Critical Care Fellow San Juan City Hospital San Juan, Puerto Rico

Melanie Krongold, MD

Pulmonary and Critical Care Medicine Chief Fellow Lincoln Medical Center Bronx, NY

Jennifer Weber, FNP-BC, APRN

Yale Center for Asthma and Airway Disease New Haven, CT

DISCLOSURE OF FINANCIAL RELATIONSHIPS

The mission and vision of CHEST include our commitment to providing accurate, balanced, evidence-based information to health care professionals participating in this educational course. To guarantee our accredited continuing education is fair and balanced and that any clinical content presented supports safe, effective patient care, we require all planners, faculty, and others in control of educational content to complete and submit financial disclosures of all relationships with <u>Accreditation Council for Continuing Medical Education-defined ineligible companies</u> within the prior 24 months. We value the contributions of those who are committed and passionate about pulmonary medicine and want to be a part of our educational courses; however, it is our commitment to our learners to have continuing education free of commercial bias and marketing.

Identified conflicts of interest are reviewed by the educational course director/chair, the Accreditation Team, and/or the Professional Standards Committee to ensure conflicts are properly mitigated. CHEST educational standards pertaining to conflict of interest are intended to ensure the delivery of balanced, evidence-based, scientific presentations. Disclosure of any or no relevant financial relationships will be made available online in course materials and on-site during all educational courses.

The following faculty/planner members of this course have disclosed to CHEST that they have a relevant <u>financial relationship</u> with a commercial interest as it relates to the course:

Name	Role	Disclosure
Sandra G. Adams, MD, MS, FCCP	Planner	Educational/grant research support:
		Educational/grant research support:
		AstraZeneca, Boehringer Ingelheim,
		GlaxoSmithKline, and Sunovion
		Founder and president: WipeDiseases
		Foundation
Frank C. Albers, PhD	Planner	Employee of Avillion
Praveen Akuthota	Planner	Consultant: AstraZeneca, GlaxoSmithKline,
		Sanofi, and Connect Biopharma
		Research: Regeneron, National Institutes of
		Health, and American Partnership for
		Eosinophilic Disorders
		Royalties: UpToDate
Richard Beasley, DSc	Planner	Grant funding: AstraZeneca, Cure Kids, Health
		Research Council of New Zealand, Genentech,
		and GlaxoSmithKline
		Personal fees: AstraZeneca, Avillion, Cipla, and
		Theravance
		Advisory board: AstraZeneca, Avillion, and
		Theravance
		Chair: Asthma and Respiratory Foundation NZ
Andrew R. Berman, MD, MHA	Planner	Consultant: ANI Pharmaceuticals
Alvise Berti, MD	Planner	Fellowship grant: Vasculitis Clinical Research
		Consortium
Christy Cappelletti, PharmD	Planner	Employee and stockholder: AstraZeneca
Bradley E. Chipps, MD	Planner	Advisory board and speaker: AstraZeneca,
		Boehringer Ingelheim, Genentech,
		GlaxoSmithKline, Novartis, Regeneron, and Sanofi
Divi Cornec, MD, PhD	Planner	Fellowship grant: French Society of Rheumatology
		and Brest University Hospital
Gregory P. Cosgrove, MD, FCCP	Planner	Consultant: Boehringer Ingelheim and Global

		Academy
		Grant research: Bristol Myers Squibb, Global
		Blood Therapeutics, and Pulmonary Fibrosis Foundation
		Honoraria and advisory: Genentech, Global Therapeutics, and Veracyte
		Advisory and consultant: Boehringer Ingelheim, InterMune, and Pulmonary Fibrosis (support to National Jewish Health)
Borja G. Cosio, MD, PhD	Planner	Advisory board: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Rovi, Sanofi, and Teva
Grainne D'Ancona, MSc	Planner	Advisory board, grant research, and educational support: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Napp, Pfizer, Sanofi, and Teva
Anna Danilewicz, BSc (Hons)	Planner	Employee of Avillion
Paul F. Dellaripa, MD	Planner	Advisory board: US Food and Drug Administration Royalties: UpToDate
Lynn Dunsire, MSc	Planner	Employee and stockholder: AstraZeneca
Jonathan Grigg, MD	Planner	Personal fees: AstraZeneca, GlaxoSmithKline, Novartis, and Vifor Pharma
Atul Gupta MD(Res)	Planner	Clinical trials: Airsonet, Boehringer Ingelheim, GlaxoSmithKline, and Novartis Director: Paediatric Respiratory Academy Speaker and advisory board: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis
Nicola A. Hanania, MD	Planner	Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Roche, Sanofi, and Teva Research support: AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, Roche, and Sanofi
Elliot Israel, MD	Planner	Personal fees: AB Science, Allergy and Asthma Network, Biometry, Equillium, Merck, NHLBI, 4D Pharma, Pneuma Respiratory, PPS Health, Regeneron, Sanofi, and Sienna Biopharmaceuticals Grants and personal fees: Amgen, AstraZeneca, Avillion, and Novartis Personal fees and support: Genentech, GlaxoSmithKline, Teva, and Circassia Grants: Gossamer Bio Support: Boehringer Ingelheim

		and Vorso Corp
Eva Johnsson, MD	Planner	Employee and stockholder:
ĺ		AstraZeneca
Sandhya Khurana, MD, FCCP	Planner	Research funding: American
, , ,		Lung Association
		Royalties: Springer Nature
Monica Kraft, MD, FCCP	Planner	Clinical trials: AstraZeneca,
, ,		Chiesi, Sanofi, and Regeneron
		Consultant: AstraZeneca,
		Gossamer, Ionis, Sanofi, and
		Regeneron
		Editor: Elsevier
		Owner/founder: RaeSedo, LLC
		Research support: Chiesi,
		National Institutes of Health,
		and Sanofi
		Royalties: Elsevier
Njira Lugogo, MD	Planner	Consultant: Teva,
, , , , , , , , , , , , , , , , , , , ,		GlaxoSmithKline, AstraZeneca,
		Sanofi, Genentech, Regeneron,
		and Amgen
		Speaker: Niox Group,
		AstraZeneca, GlaxoSmithKline,
		and Teva
Neil R. MacIntyre, MD, FCCP	Planner	Consultant: Hillrom, Inspirx, and Ventec
	Planner	Research: Boehringer Ingelheim, Canadian
Darcy D. Marciniuk, MD, Master FCCP,		Institutes of Health Research, Lung Association of
FCAHS, FRCPC		Saskatchewan, University of Saskatchewan,
		McGill University Research Institute, Parexel,
		Pearl Therapeutics, and Syneos Health
Diego J. Maselli, MD, FCCP	Planner/Co-Chair	Consultant and speaker: Amgen, AstraZeneca,
		GlaxoSmithKline, Sanofi, and Regeneron
Peter J. Mazzone, MD, MPH, FCCP	Planner	Research funding: Adela, Biodesix, DELFI, Exact
		Sciences, Nucleix, and Veracyte
Arjun Mohan, MD	Planner	Advisory board: Verona Pharmaceuticals
		and Regeneron
lan S. Mudway, PhD	Planner	Financial support: National Institute for
	D1	Health Research and Public Health England
S. Shahzad Mustafa, MD	Planner	Speaker: Genentech, Regeneron, Sanofi,
		GlaxoSmithKline, AstraZeneca, and CSL
		Behring
Alexandra MA Newson DED	Diaman	Grant funding: Takeda
Alexandra M. Nanzer, PhD	Planner	Congress support: Napp Speaker: AstraZeneca, Chiesi, and Teva
Philip Ong MD ECCD	Planner	Consultant: Pulmonx and Pinnacle Biologics
Philip Ong, MD, FCCP Reynold A. Panettieri, MD	Planner	Grants and advisory: AstraZeneca, Sanofi,
	i idillici	Genentech, Medlmmune, Origa Pharma,
		Amgen, RIFM, National Institutes of Health,
		Regeneron, and Novartis
Alberto Papi, MD	Planner	Grant funding: Chiesi, AstraZeneca,
	i diffici	GlaxoSmithKline, Boehringer Ingelheim,
		Teva, and Sanofi
		Advisory board: Chiesi, AstraZeneca,

		GlaxoSmithKline, Boehringer Ingelheim,
		Novartis, Sanofi, IQVIA, Avillion, Elpen, Menarini, Zambon, and Mundipharma
Luis Perez de Llano, MD, PhD	Planner	Advisory board: AstraZeneca, Gebro, Chiesi, GlaxoSmithKline, Bial, Novartis, Rovi, Sanofi, and Teva
Anju Peters, MD, MSCI	Planner	Advisory board: AstraZeneca, Optinose, Sanofi, and Regeneron Consultant: AstraZeneca, Novartis, Optinose, Sanofi, and Regeneron Research support: AstraZeneca and Optinose
Paul E. Pfeffer, PhD	Planner	Grant support: GlaxoSmithKline Support: AstraZeneca and GlaxoSmithKline Personal fees: AstraZeneca and Novartis
Robert Rees, PhD	Planner	Employee of Avillion
Linda Rogers, MD, FCCP	Planner	Advisory committee: AstraZeneca, Novartis, and Sanofi Clinical investigator: AstraZeneca and Sanofi Consultant: AstraZeneca, Sanofi, and Teva Educational content developer: AstraZeneca and Genentech Educational grant: AstraZeneca Research support: AstraZeneca and Sanofi
Christian E. Sandrock, MD, MPH, FCCP	Planner	Honoraria and speaker: Allergan
Audra Schwalk, MD, MBA	Planner	Consultant and advisory board: Ambu
Mary E. Strek, MD, FCCP	Planner	Committee member: FibroGen Medical writing assistance: Boehringer Ingelheim and Galapagos
Nuria Toledo-Pons, MD, PhD	Planner	Speaker fees and travel: AstraZeneca, Sanofi, and GlaxoSmithKline
Jennifer Weber, APRN-BC	Faculty	Advisory committee: AstraZeneca
Michael Wechsler, MD	Planner	Consultant: AstraZeneca, Boehringer Ingelheim, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, and Teva Data and safety monitoring board: Sentien Biotechnologies Investigator: AstraZeneca, GlaxoSmithKline, Sanofi, and Teva
		Speaker: GlaxoSmithKline and Sanofi

The remaining faculty/planner members of this course who are not listed in the grid above have indicated to CHEST that they have <u>no relevant financial relationships</u> with any commercial interests.

CHEST CME Credit Staff Planners

The following CME Credit Staff Planners have no financial relationships to disclose:

Conrad Allen Morgan Bashford Kaitlyn Chisholm Dada, MA, MFA Shaun Davies Morgan Jacobus



Carolyn Jones Greg Lasko, MA, HRD Amna Moustafa Martha Zaborowski Pascale, CPM Richard Schuch, EdD Jenny Szabo, CAE Kara Victorsen

CME/CE CREDIT INFORMATION

CME/CE Credit Claim Instructions CHEST Curriculum Pathway for Asthma

To complete the Education Course Evaluation for CHEST Curriculum Pathway for Asthma, claim CME/CE credits, and download CME/CE certificates and certificates of attendance (COA), please see the instructions below. You must complete your evaluation and download your certificate prior to the product expiration date.

- 1. Sign in and navigate to your "My Learning" account at education.chestnet.org.
- 2. Find the course or event in your list and complete all required post-course work.
- 3. Claim credits when prompted.

Your certificate and transcript can be viewed at any time under Claimed Courses on the Manage CME page.

If you are claiming MOC points, please make sure that your full name, date of birth, and American Board of Internal Medicine (ABIM) number listed in your CHEST account match what is listed in your ABIM account. To prevent delays in receiving MOC points, please check that your ABIM account is current.

If you need help, contact the CHEST Accreditation Team at cme@chestnet.org. For faster assistance, outline the specific problem you are having, and provide your CHEST ID and contact information.

YOU MUST COMPLETE THE POST-COURSE ASSESSMENT AND EDUCATION COURSE EVALUATION PRIOR TO THE PRODUCT EXPIRATION DATE July 20, 2028

Physician Credit

The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Chest Physicians designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credit $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the course.

Nursing Credit

The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American College of Chest Physicians designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credits™.



One AMA PRA Category 1 Credit™ is equal to one contact hour for the following professional certification organization:

- American Nurses Association (ANCC))
- American Association of Nurse Practitioners (AANP)

For registered nurses, please check your state licensing board for CME equivalency.

Nurse Practitioners

The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American College of Chest Physicians designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credits™.

One AMA PRA Category 1 Credit™ is equal to one contact hour for the following professional certification organization:

• The American Academy of Nurse Practitioners Certification Board (AANPCB)

Physician Assistants

The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American College of Chest Physicians designates this live activity for a maximum of 20.75 *AMA PRA Category 1 Credits™*.

One AMA PRA Category 1 Credit™ is equal to one contact hour for the following professional certification organizations:

- American Academy of Physical Associates (AAPA)
- The National Commission on Certification of Physician Assistants (NCCPA)

COA

The American College of Chest Physicians confirms that the individual named below has participated in this educational activity.

The American College of Chest Physicians designates this live activity for a maximum of 20.75 *AMA PRA Category 1 Credits™*. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification Statement

Successful completion of this CME credit course enables the participant to earn up to 20.75 MOC Part 2 Medical Knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the course. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Upon successful completion of this course, CHEST will submit your completion data to ABIM via ACCME's Program and Course Reporting System (PARS) for MOC points. To prevent delay in receiving your ABIM points, please make sure that your ABIM number, birth date, and full name in your CHEST account match your ABIM account. Please also make sure that your ABIM account is current. After claiming CME credits, please allow 3-5 business days after claiming for credits to show in your ABIM record.

DISCLAIMER

The American College of Chest Physicians ("CHEST") and its officers, regents, executive committee members, members, related entities, employees, representatives, and other agents (collectively, "CHEST Parties") are not responsible in any capacity for, do not warrant, and expressly disclaim all liability for, any content whatsoever in any CHEST publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from



any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any CHEST publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of CHEST Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Copyright © 2025 by the American College of Chest Physicians.

Copyright not claimed on material authorized by the US Government.

All rights reserved. No part of this publication may be reproduced in any manner without permission of the publisher.

American College of Chest Physicians 2595 Patriot Boulevard Glenview, IL 60026

Telephone: +1 (224) 521-9800; Fax: +1 (224) 521-9801

chestnet.org